What does this research mean for the field?

Question

Accepted Answer

Lebrikizumab provides meaningful improvements in skin clearance, itch, and quality of life for patients with moderate-to-severe atopic dermatitis who previously discontinued dupilumab, without causing a recurrence of dupilumab-associated adverse events. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

Lebrikizumab Improves Clinical Manifestations, Symptoms, and Quality of Life in Patients with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab: Results from the ADapt Study

Discussion

Member takes

Overview

Key Points

Cite This Study